Akero Therapeutics Stock Analysis

Akero Stock Analysis Notes

About 99.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.93. Akero Therapeutics recorded a loss per share of 3.78. The entity had not issued any dividends in recent years. Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Akero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 37 people. For more info on Akero Therapeutics please contact Andrew MD at 650 487 6488 or go to https://akerotx.com.

Akero Therapeutics Investment Alerts

Akero Therapeutics Upcoming and Recent Events

Akero Largest EPS Surprises

View All Earnings Estimates

Akero Therapeutics Environmental, Social, and Governance (ESG) Scores

Akero Stock Institutional Investors

Note, although Akero Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Akero Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.86 B.

Akero Profitablity

Management Efficiency

Akero Therapeutics has return on total asset (ROA) of (0.2317) % which means that it has lost $0.2317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.359) %, meaning that it created substantial loss on money invested by shareholders. Akero Therapeutics' management efficiency ratios could be used to measure how well Akero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to drop to -0.29. At this time, Akero Therapeutics' Total Assets are very stable compared to the past year. As of the 31st of January 2025, Net Tangible Assets is likely to grow to about 394.3 M, though Non Currrent Assets Other are likely to grow to (1.09).

Technical Drivers

As of the 31st of January, Akero Therapeutics shows the risk adjusted performance of 0.1095, and Mean Deviation of 4.57. Akero Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Akero Therapeutics Price Movement Analysis

Akero Therapeutics Insider Trading Activities

Akero Therapeutics Outstanding Bonds

Akero Therapeutics Predictive Daily Indicators

Akero Therapeutics Corporate Filings

Akero Therapeutics Forecast Models

Akero Therapeutics' time-series forecasting models are one of many Akero Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Akero Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Akero Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Akero shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Akero Therapeutics. By using and applying Akero Stock analysis, traders can create a robust methodology for identifying Akero entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Akero analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Akero analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Akero Therapeutics stock analysis indicators help investors evaluate how Akero Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Akero Therapeutics shares will generate the highest return on investment. By understating and applying Akero Therapeutics stock analysis, traders can identify Akero Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.